Primary vs. secondary antibody deficiency: Clinical features and infection outcomes of immunoglobulin replacement

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Duraisingham, Sai S ^a   Buckland, Matthew ^a   Dempster, John ^a   Lorenzo, Lorena ^a   Grigoriadou, Sofia ^a   Longhurst, Hilary J ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BRONCHIECTASIS; CANCER CHEMOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; DELAYED DIAGNOSIS; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIMARY ANTIBODY DEFICIENCY; PROGNOSIS; RHEUMATIC DISEASE; SECONDARY ANTIBODY DEFICIENCY; X LINKED AGAMMAGLOBULINEMIA; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; OUTCOME ASSESSMENT; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AGED, 80 AND OVER; BRONCHIECTASIS; COHORT STUDIES; DELAYED DIAGNOSIS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903544224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100324     Document Type: Article

References (50)

1. Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, et al. (2013) A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol 33: 1078-1087.
2. Castigli E, Geha RS (2006) Molecular basis of common variable immunodeficiency. J Allergy Clin Immunol 117: 740-746.
3. Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ (2014) Secondary antibody deficiency. Expert Rev Clin Immunol 10: 583-591.
4. Herriot R, Sewell WA (2008) Antibody deficiency. J Clin Pathol 61: 994-1000.
5. Rose ME, Lang DM (2006) Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med 73: 133-137, 140, 143-134.
6. Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, et al. (2013) Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma 54: 99-104.
7. Griffiths H, Lea J, Bunch C, Lee M, Chapel H (1992) Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 89: 374-377.
8. Bernatsky S, Hudson M, Suissa S (2007) Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46: 1157-1160. (Pubitemid 47050621)
9. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, et al. (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 51: 833-840.
10. Yomota M, Amano I, Horita N, Takezawa T, Arai T, et al. (2012) Serum immunoglobulin G is a marker for the risk of opportunistic infection in steroid-dependent severe asthmatic patients. Intern Med 51: 2715-2719.
11. Ozaras N, Goksugur N, Eroglu S, Tabak O, Canbakan B, et al. (2012) Carbamazepine-induced hypogammaglobulinemia. Seizure 21: 229-231.
12. Strober W, Wochner RD, Carbone PP and Waldmann TA (1967) Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest 46: 1643-1656.
13. Salzer U, Warnatz K, Peter HH (2012) Common variable immunodeficiency - an update. Arthritis Res Ther 14: 223.
14. Baris S, Ercan H, Cagan HH, Ozen A, Karakoc-Aydiner E, et al. (2011) Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency. J Investig Allergol Clin Immunol 21: 514-521.
15. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, et al. (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112: 277-286.
16. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, et al. (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125: 1354-1360 e1354.
17. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM (2010) Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 137: 21-30.
18. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, et al. (2011) Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 31: 315-322.
19. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343: 1059-1063. (Pubitemid 24128204)
20. Co-operative group for the study of immunoglobulins in CLL (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. New Engl J Med 319: 902-907.
21. Gunther G, Dreger B (2013) Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiol Immunol 57: 527-535.
22. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, et al. (1996) Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81: 121-126.
23. Edgar JD, Buckland M, Guzman D, Conlon NP, Knerr V, et al. (2014) The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012. Clin Exp Immunol 175: 68-78.
24. Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, et al. (2014) Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol (In press).
25. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, et al. (2011) Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2: 54.
26. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, et al. (2005) Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94: S1-63.
27. Conley ME, Notarangelo LD, Etzioni A (1999) Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93: 190-197.
28. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, et al. (2012) Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130: S1-24.
29. Bright P, Grigoriadou S, Kamperidis P, Buckland M, Hickey A, et al. (2013) Changes in B cell immunophenotype in common variable immunodeficiency: cause or effect - is bronchiectasis indicative of undiagnosed immunodeficiency? Clin Exp Immunol 171: 195-200.
30. Wood P, Stanworth S, Burton J, Jones A, Peckham DG, et al. (2007) Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 149: 410-423. (Pubitemid 47256150)
31. Blore J, Haeney MR (1989) Primary antibody deficiency and diagnostic delay. BMJ 298: 516-517. (Pubitemid 19072086)
32. Seymour B, Miles J, Haeney M (2005) Primary antibody deficiency and diagnostic delay. J Clin Pathol 58: 546-547. (Pubitemid 40646879)
33. Chapel H, Cunningham-Rundles C (2009) Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 145: 709-727.
34. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, et al. (2008) The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111: 77-85.
35. Mouthon L, Fermand JP, Gottenberg JE (2013) Management of secondary immune deficiencies: what is the role of immunoglobulins? Curr Opin Allergy Clin Immunol 13 Suppl 2: S56-67.
36. Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, et al. (2009) The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol 157 Suppl 1: 3-11.
37. Yip NH, Lederer DJ, Kawut SM, Wilt JS, D'Ovidio F, et al. (2006) Immunoglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med 173: 917-921.
38. Shortt J, Spencer A (2006) Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 38: 433-436. (Pubitemid 44340374)
39. Casulo C, Maragulia J, Zelenetz AD (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13: 106-111.
40. Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, et al. (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 7: e37626.
41. Becerra E, Cambridge G, de la Torre I, Leandro MJ (2012) Long-term safety of rituximab in patients with rheumatoid arthritis. Int J Clin Rheumatol 7: 383-390.
42. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833. (Pubitemid 28363048)
43. Makatsori M, Kiani-Alikhan S, Manson A, Verma N, Leandro M, et al. (2014) Hypogammaglobulinaemia after rituximab treatment- its incidence and outcome. QJM (In press).
44. Kawano T, Matsuse H, Obase Y, Kondo Y, Machida I, et al. (2002) Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol 128: 240-243. (Pubitemid 34765231)
45. Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U (2013) What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 13: 2601-2610.
46. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C (2012) Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 119: 1650-1657.
47. Piqueras B, Lavenu-Bombled C, Galicier L, Bergeron-van der Cruyssen F, Mouthon L, et al. (2003) Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 23: 385-400. (Pubitemid 37083193)
48. Warnatz K, Denz A, Drager R, Braun M, Groth C, et al. (2002) Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99: 1544-1551. (Pubitemid 34533024)
49. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, et al. (2006) Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 107: 3045-3052.
50. Boumans MJ, Thurlings RM, Gerlag DM, Vos K, Tak PP (2011) Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis Rheum 63: 3187-3194.